(to be used for a	ANSMITTAL FORM	Application Number Filing Date First Named Inventor Art Unit Examiner Name	C	PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 Trademark Office; U.S. DEPARTMENT OF COMMERCE formation unless it displays a valid OMB control number. 1472, 964 09-26-2003 Frank Bennett
		T101 00117F0		
Amendme Aff Aff Aff Extension Express A Informatio Certified C Document Reply to M Incomplete	iter Final ifidavits/declaration(s) of Time Request Abandonment Request on Disclosure Statement Copy of Priority	Drawing(s) Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocatic Change of Correspondence Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on Comparison Comparis	Address	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please Identify below):
Firm Name	SIGNA	TURE OF APPLICANT, ATTO	ORNEY, C	OR AGENT
Filli Ivanic	Isis Pharmaceuticals, Inc.			
Signature	4 Journe	Alla O		
Printed name	Donna T. Ward, Ph.D.			
Date	9/80/05		Reg. No.	48,271
	C	ERTIFICATE OF TRANSMISS	SION/MA	ILING
I hereby certify the sufficient postage the date shown be Signature	as first class mail in an en	eing facsimile transmitted to the USP velope addressed to: Commissioner f	TO or depos or Patents,	sited with the United States Postal Service with P.O. Box 1450, Alexandria, VA 22313-1450 on

Typed or printed name

Pamela Grooms

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the eperwork Reduct

PTO/SB/82 (09-04)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

REVOCATION OF POWER OF ATTORNEY WITH NEW POWER OF ATTORNEY AND

Application Number	See Attached Table
Filing Date	See Attached Table
First Named Inventor	See Attached Table
Art Unit	
Examiner Name	
Attorney Docket Number	See Attached Table

CHANGE OF CORRESPONDENCE ADDRESS

I hereby re	voke all pre	evious powers of a	attornev given i	in the a	above-id	entified appl	ication.	
☐ A Pow	er of Attorn	ey is submitted her	ewith.					
OR I here	by appoint	the practitioners as	sociated with the	e Custo	omer Nur	nber:	5:	5,389
l _		e correspondence a	iddress for the a	bove-id	dentified	application to	:	
_ c	ustomer Nu			55,38	39			
OR Firm o	i.							
	r ual Name							
Address								
City			****	State			Zip	ı
Country								
Telephone					Fax			
I am the: App	licant/Inven	tor.				- 		
ু Assi	gnee of rec	ord of the entire int						
		SIGNATUR	RE of Applicant	or As	signee o	f Record		
Signature	Sto	Buja						
Name	Grantland E.	Bryce, Esq.						
Date	09/29/2005				elephone	700 001 020		
NOTE: Signature signature is requ	s of all the inventred, see below*.	tors or assignees of record	of the entire interest o				mit multiple	forms if more than one
*Total	of 1	forms are submitted.						

This collection of information is required by 37 CFR 1.36. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OCT 0 8 2005 OUT OF THE PROPERTY ACT OF

PTO/SB/96 (09-04)
Approved for use through 07/31/2006. OMB 0651-0031
S. Palent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Page work Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

STATEMENT	<u>UNDER 37 CFR 3.73(b)</u>
Applicant/Patent Owner: Isis Pharmaceuticals, Inc	
Application No./Patent No.: See Attached Table File	ed/issue Date: See Attached Table
Entitled: See Attached Table	
Isis Pharmaceuticals, Inc. , a (Name of Assignee)	Corporation (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)
states that it is: 1. the assignee of the entire right, title, and interest; of the entire right, title, and the entire right, the	or
2. an assignee of less than the entire right, title and in The extent (by percentage) of its ownership interest.	
in the patent application/patent identified above by virtue	of either:
An assignment from the inventor(s) of the patent a in the United States Patent and Trademark Office a thereof is attached. OR	application/patent identified above. The assignment was recorded at Reel See Attached Table, or for which a copy
	pplication/patent identified above, to the current assignee as shown
The document was recorded in the United S	To:
From:	To:
From: The document was recorded in the United S	To:
Reel, Frame	States Patent and Trademark Office at, or for which a copy thereof is attached.
Additional documents in the chain of title are list	ted on a supplemental sheet.
Copies of assignments or other documents in the cha [NOTE: A separate copy (i.e., a true copy of the original Division in accordance with 37 CFR Part 3, if the MPEP 302.08]	nin of title are attached. inal assignment document(s)) must be submitted to Assignment e assignment is to be recorded in the records of the USPTO. See
The undersigned (whose title is supplied below) is author	-
Signature	09/29/2005 Date
Grantland E. Bryce, Esq.	
Printed or Typed Name	Telephone Number
Vice President and General Counsel	
Title	

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Reel Frame
08/15/2003 ACTIVATED PROTEIN KINASE EXPRESSION 15303 640
ANTISENSE MODULATION OF SUPEROXIDE 15848 152 DISMUTASE 1, SOLUBLE EXPRESSION
16190 206
16546
MODULATION OF APOLIPOPROTEIN C-III 13991 266 EXPRESSION
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN
MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN- LIKE GROWTH FACTOR EXPRESSION
MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN- LIKE GROWTH FACTOR EXPRESSION
MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN- LIKE GROWTH FACTOR EXPRESSION
MODULATION OF GROWTH HORMONE RECEPTOR EXPRESSION AND INSULIN- LIKE GROWTH FACTOR EXPRESSION
ANTISENSE MODULATION OF STEAROYL- 13206 841 COA DESATURASE EXPRESSION
ANTISENSE MODULATION OF STEAROYL- COA DESATURASE EXPRESSION 13206 841
15031 790
14711

